Subscribe for the newsletter
Sign in
Articles
Expert Interviews
Roundtable
Press Releases
Videos
The Road To Series
Market Research
Thought Leaders
More
Discovery
Small Molecules
Biologics
Advanced Therapies
Manufacturing
Supply Chain
Clinical Trials
Technologies
Financing
Eisai Co., Ltd.
Sort By
Newest First
1 / 1
1 / 1
FDA Approval
Eisai And Merck Announce FDA Approval Of LENVIMA® (lenvatinib) Capsules For First-line Treatment Of Unresectable Hepatocellular Carcinoma (HCC)
Eisai
PR-M09-18-NI-070
Sep 24, 2018
Study Results
Eisai And Biogen Present Detailed Results From Phase II Clinical Study Of Elenbecestat In MCI And Mild To Moderate Alzheimer's Disease
Eisai
PR-M07-18-NI-103
Jul 31, 2018
Drug Discovery
Eisai Inc. to Launch Center for Genetics Guided Dementia Discovery in Cambridge, Massachusetts
Eisai
PR-M06-18-NI-044
Jun 13, 2018
Strategic Collaboration
Eisai Co., Ltd. and Merck Enter Global Strategic Oncology Collaboration for LENVIMA® (lenvatinib mesylate)
Eisai
PR-M03-18-NI-046
Mar 13, 2018
Breakthrough Therapy
Eisai and Merck Receive Breakthrough Therapy Designation from FDA for LENVIMA® (lenvatinib mesylate) and KEYTRUDA® (pembrolizumab) as Combination Therapy
Eisai
PR-M01-18-NI-032
Jan 12, 2018
